Vetaş
Vetaş is a Turkish veterinary pharmaceutical brand operating under DEVA Holding since 1973, manufacturing and distributing animal health products across seven therapeutic areas to veterinarians and animal breeders in Turkey.
- Company typePrivate
- Founded1973
- HeadquartersIstanbul, Türkiye
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Vetaş does
Vetaş is a Turkish veterinary pharmaceutical brand that has operated under DEVA Holding since its founding in 1973. The company manufactures and distributes veterinary health products across seven therapeutic areas — antibacterials, antiparasites, vitamins/minerals/aminoacids, hormones, aquaculture products, disinfectants, and other veterinary medications — serving veterinarians and animal breeders in Turkey. Its portfolio includes legacy brands such as Vetimisin (a penicillin product that has held market leadership since launch in 1973), the Gentavet gentamicin line, Fiproteam fipronil-based antiparasitics, and aquaculture products such as Diaqua, alongside more recent entries into the companion animal (pet) category.
Products are produced at DEVA Holding's manufacturing infrastructure, which includes four facilities in Çerkezköy and Kartepe equipped with GMP certifications and, in the case of Kartepe, US FDA approval. The Çerkezköy-I plant produced 183 million boxes in 2025, supported by the Çerkezköy-IV Logistics Center with 43,500 pallet capacity — described as one of Turkey's largest pharmaceutical logistics centers. R&D is conducted through the DEVARGE center, a multidisciplinary operation with 400+ researchers covering pharmaceutical development, API synthesis, biotechnology, biosimilar development, and analytical/CMC work.
Vetaş operates a sales-led, professional-channel go-to-market model, distributing directly to veterinarians and animal breeders through dedicated sales representatives and reseller networks. Marketing is anchored on the Vetakademi Kampüs scientific education program for veterinarians and Vademekum product catalogs. The brand is wholly consolidated within DEVA Holding (itself majority-owned since 2006 by EastPharma Limited, a GEM Global affiliate), following Vetaş's 2016 merger into the parent.
Vetaş firmographics
Firmographics- Name
- Vetaş
- Legal name
- Vetaş
- Website
- https://vetas.com.tr
- Company type
- Private
- Founded year
- 1973
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vetaş is a Turkish veterinary pharmaceutical brand operating under DEVA Holding since 1973, manufacturing and distributing animal health products across seven therapeutic areas to veterinarians and animal breeders in Turkey.
- Ownership category
- akta.pro rank
Vetaş industry classification
Industry- Product category
- Veterinary Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)
- akta.pro secondary industries
- Specialty Veterinary Therapeutics Distribution (Oncology, Dermatology, Endocrinology) (HLAMAIAH), Animal Health OTC Retail (Parasite Control, Basic Care) (HLAMAIAJ)
Keywords
Where Vetaş is headquartered
LocationHeadquarters
- HQ city
- Istanbul
- HQ country
- Türkiye
- HQ region
- Europe
Offices4 records
Markets served
Vetaş business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Veterinary Pharmaceutical Products: Vetaş generates revenue through the sale of veterinary health products across 7 therapeutic areas including antibacterials, antiparasites, vitamins/minerals/aminoacids, hormones, aquaculture products, disinfectants, and other veterinary medications. Products are sold to veterinarians and animal breeders.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Vetaş product offering
Product offeringCore offering
Vetaş manufactures and markets veterinary pharmaceutical products across seven therapeutic areas (antibacterials, antiparasites, vitamins/minerals/aminoacids, hormones, aquaculture products, disinfectants, and other veterinary medications) for veterinarians and animal breeders in Turkey. Products are manufactured at DEVA Holding's GMP-certified and US FDA-approved facilities in Çerkezköy and Kartepe, and distributed through professional animal health channels. The portfolio includes legacy brands such as Vetimisin and Gentavet as well as newer categories such as pet companion animal products launched since 2023.
Product overview
Vetaş is a veterinary pharmaceutical company operating under DEVA Holding since 1973. The company offers a broad product portfolio across 7 therapeutic areas including Antibacterials, Antiparasites, Vitamins/Minerals/Aminoacids, Hormones, Aquaculture Products, Disinfectants, and Other Products. Key products include Vetimisin (penicillin market leader since 1973), Gentavet line (gentamicin-based antibiotics), Geosol (oxytetracycline products), Fiproteam (fipronil-based antiparasitics), and various hormone products like Vetaş Oksitosin and Vetaş Atropin. Products are manufactured at DEVA Holding's GMP-certified facilities in Çerkezköy and Kartepe, serving veterinarians and animal breeders across Turkey.
Differentiator
Problem solved
Functional benefit
Products and services
- Fourquinom %2,5 Enjeksiyonluk Süspansiyon
Quantifiable outcome
- Vetimisin has maintained penicillin market leadership since first day of launch in 1973
- +2 more outcomes
Companies that use Vetaş
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Vetaş technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Vetaş partnerships and signals
Strategic signalScale indicators7 records
Recent moves10 records
Expansion highlights6 records
Vetaş competitors and assessment
Company assessmentBroad incumbents
- Elanco Animal Health: Elanco is a major global animal health company with deep portfolios in livestock and companion animal pharmaceuticals. A broad incumbent competing with Vetaş across multiple therapeutic categories.
- MSD Animal Health (Merck): MSD Animal Health (Merck) is a leading global animal health division offering pharmaceuticals, vaccines, and health management solutions. Competes broadly with Vetaş in antibacterials, parasiticides, and vaccines in Turkey.
- Boehringer Ingelheim Animal Health: Boehringer Ingelheim's Animal Health division is one of the global top players in veterinary pharmaceuticals, vaccines, and therapeutics. A larger incumbent operating broadly across the same product categories as Vetaş in Turkey.
Direct peers
- Ceva Santé Animale: Ceva is a global veterinary pharmaceutical company headquartered in France, with strong positions in poultry, swine, ruminants, and companion animal therapeutics including vaccines and pharmaceuticals. Directly comparable to Vetaş's mixed livestock/companion animal focus.
- Virbac: Virbac is a France-based global veterinary pharmaceutical company with a broad portfolio across antibacterials, parasiticides, vaccines, and specialty therapeutics for companion and farm animals. It is one of the closest direct comparables to Vetaş in terms of portfolio breadth and channel model.
- Vetoquinol: Vetoquinol is an independent French veterinary pharmaceutical company focused on livestock and companion animal health products, with a portfolio spanning anti-infectives, parasiticides, and supportive therapies. Closely comparable to Vetaş in therapeutic area coverage and distribution approach.
- Phibro Animal Health: Phibro Animal Health is a US-based diversified animal health and mineral nutrition company serving livestock and aquaculture producers globally. Directly comparable to Vetaş in livestock-focused pharmaceutical portfolio, particularly in aquaculture.
- Zoetis: Zoetis is the world's largest pure-play animal health company, offering pharmaceuticals, vaccines, diagnostics and medicated feed additives across companion and livestock animals. It is the global benchmark Vetaş competes against in antibacterials, parasiticides, vaccines, and aquaculture products.
- Dechra Pharmaceuticals: Dechra is a UK-based specialty veterinary pharmaceuticals company focused on companion animal and livestock therapeutics, with strengths in endocrinology, dermatology, and anti-infectives. Comparable to Vetaş in therapeutic category focus and channel-to-veterinarian model.
Emerging players
- Alivira Animal Health: Alivira is an India-based veterinary pharmaceutical company with a broad portfolio across antibacterials, parasiticides, and nutritionals, with regional focus in South Asia, Middle East, and Africa. Comparable emerging-market peer with similar portfolio breadth and channel model to Vetaş.
Market position
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Vetaş social profiles
Digital presenceVetaş compliance and trust
Trust signalCompliance2 records
Vetaş financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vetaş leadership team
Management profileNumber of profiles
Vetaş funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vetaş M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vetaş
What does Vetaş do?
Vetaş manufactures and markets veterinary pharmaceutical products across seven therapeutic areas (antibacterials, antiparasites, vitamins/minerals/aminoacids, hormones, aquaculture products, disinfectants, and other veterinary medications) for veterinarians and animal breeders in Turkey. Products are manufactured at DEVA Holding's GMP-certified and US FDA-approved facilities in Çerkezköy and Kartepe, and distributed through professional animal health channels. The portfolio includes legacy brands such as Vetimisin and Gentavet as well as newer categories such as pet companion animal products launched since 2023.
Is Vetaş a public or private company?
Vetaş is a private company. It is classified as corporate owned and is currently operating.
When was Vetaş founded?
Vetaş was founded in 1973. It employs 11 to 50 people.
Where is Vetaş based?
Vetaş is headquartered in Istanbul, Türkiye, in the Europe region.
How does Vetaş make money?
One revenue line is on record: veterinary Pharmaceutical Products.
Who are Vetaş's main competitors?
Broad incumbents on record are Elanco Animal Health, MSD Animal Health (Merck) and Boehringer Ingelheim Animal Health. Direct peers are Ceva Santé Animale, Virbac, Vetoquinol, Phibro Animal Health, Zoetis and Dechra Pharmaceuticals. Alivira Animal Health is listed as an emerging player.
Does Vetaş have an API?
No public API is recorded for Vetaş.
What industry is Vetaş in?
Vetaş's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is AFAEANAK, Veterinary Pharmacy, Vaccine & Biologics Services, with a secondary code of HLAMAIAH, Specialty Veterinary Therapeutics Distribution (Oncology, Dermatology, Endocrinology). Its NAICS code is 325414 and its SIC code is 2834.